Roche bullish on Alzheimer's prospects
This article was originally published in Scrip
Roche has reported a solid performance for the first half of 2015 and provided a promising, though data-light, R&D update. A number of Phase III starts and filing timelines have been confirmed, and the Swiss pharma also gave an update on its Alzheimer's ambitions.
You may also be interested in...
Biogen rose and fell based on the company’s latest aducanumab results, but the Clinical Trials on Alzheimer’s Disease meeting Dec. 8-10 showed that regardless of Lilly’s Phase III solanezumab failure, companies continue to invest in amyloid and other hypotheses, including BACE, gamma secretase and other programs.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.